Subject: Ibrance SGM 1726-A P2026

Drug

IBRANCE  (palbociclib)

Policy:

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications^1,2

Ibrance is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:

·        an aromatase inhibitor as initial endocrine based therapy, or

·        fulvestrant in patients with disease progression following endocrine therapy.

Ibrance is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.

Compendial Uses^3-5

·        Breast cancer

·        Soft tissue sarcoma

·        Uterine neoplasms:

o   Endometrial carcinoma

o   Uterine sarcoma

All other indications are considered experimental/investigational and not medically necessary.

Documentation

Submission of the following is necessary to initiate the prior authorization review:

·        Documentation of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status, where applicable.

·        Documentation of test confirming presence of PIK3CA mutation, where applicable.

·        Documentation of estrogen receptor status, where applicable.

Coverage Criteria

Breast Cancer^1-3

Authorization of 12 months may be granted for treatment of HR-positive, HER2-negative recurrent unresectable, advanced, or metastatic breast cancer when one of the following criteria is met:

·        The requested medication is used in combination with an aromatase inhibitor (e.g., anastrozole, exemestane, letrozole).

·        The requested medication is used in combination with fulvestrant.

Authorization of 12 months may be granted for treatment of endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative locally advanced, recurrent, or metastatic breast cancer when used in combination with inavolisib and fulvestrant.

Soft Tissue Sarcoma^3,4

Authorization of 12 months may be granted for treatment of unresectable well-differentiated or dedifferentiated liposarcoma when used as a single agent.

Authorization of 12 months may be granted for subsequent treatment of retroperitoneal well-differentiated or dedifferentiated locally advanced or metastatic liposarcoma as a single agent.

Uterine Neoplasms^3,5

Authorization of 12 months may be granted for treatment of endometrial carcinoma with estrogen receptor (ER) positive tumors when used in combination with letrozole.

Authorization of 12 months may be granted for subsequent treatment of advanced, recurrent/metastatic, or inoperable uterine sarcoma (including adenosarcoma, endometrial stromal sarcoma (ESS), leiomyosarcoma (LMS), PEComa, and undifferentiated uterine sarcoma (UUS)) when used as a single agent.

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication outlined in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

Place of Service:

Outpatient

The above policy is based on the following references:

1.      Ibrance capsules [package insert]. New York, NY: Pfizer Inc.; September 2025.

2.     Ibrance tablets [package insert]. New York, NY: Pfizer Inc.; September 2025.

3.     The NCCN Drugs & Biologics Compendium® © 2025 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed November 13, 2025.

4.     Lexicomp [database online]. Hudson, OH: Lexi-Comp, Inc.; https://online.lexi.com/lco/action/home [available with subscription]. Accessed November 14, 2025.

5.     National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms 2.2026. https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed November 18, 2025.

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

July 14, 2026